(Total Views: 674)
Posted On: 03/25/2021 11:54:12 PM
Post# of 150014
"The aim of this study was to describe the clinical course and outcomes of four lung transplant recipients in the CD10 trial (NCT04343651): use of leronlimab (PRO 140), a novel humanized IgG4,κ monoclonal antibody to CCR5, for the treatment of mild-moderate COVID-19 illness."
Novel CCR5 Antagonist for the Treatment of Mild-Moderate COVID-19 Infection after Lung Transplant
April 2021The Journal of Heart and Lung Transplantation 40(4):S315
DOI: 10.1016/j.healun.2021.01.891
https://www.researchgate.net/publication/3502...Transplant
Novel CCR5 Antagonist for the Treatment of Mild-Moderate COVID-19 Infection after Lung Transplant
April 2021The Journal of Heart and Lung Transplantation 40(4):S315
DOI: 10.1016/j.healun.2021.01.891
https://www.researchgate.net/publication/3502...Transplant
(2)
(0)Scroll down for more posts ▼
